PolyPid Receives Buy Rating and $11 Price Target: Analyst Sees 300%+ Upside Potential Ahead of Pivotal Phase 3 Data
H.C. Wainwright has initiated coverage of PolyPid Ltd. (NASDAQ: PYPD)* with a Buy rating and an $11 price target, representing potential upside of nearly 300% from current trading levels around $2.80 per share. The bullish outlook comes as the late-stage biotech company approaches a potentially transformative topline
